Cat. No. | Product name | CAS No. |
DC23213 |
SCIO-469
A potent, selective p38α MAPK inhibitor with IC50 of 9 nM. |
309913-83-5 |
DC22577 |
Revizinone
A potent, selective PDE3 inhibitor with IC50 of 36 nM, displays >20,000-fold selectivity over PDE1.. |
133718-29-3 |
DC22963 |
Org-9935
A potent, selective PDE3 inhibitor with IC50 of 50 nM. |
129425-83-8 |
DC22942 |
BeKm-1
A potent, selective peptide inhibitor of hERG channel with IC50 of 3.3 nM for hERG1 channels. |
524962-01-4 |
DC22767 |
UK-500001
A potent, selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 26.1, 22.8, 21 and 0.28 nM for PDE4A4, PDE4B2, PDE4C2 and PDE4D3, respectively.. |
582332-31-8 |
DC11635 |
Poloxin-2
A potent, selective PLK1 PBD inhibitor with IC50 of 1.36 uM. |
1807690-39-6 |
DC22535 |
CGP-25454A
A potent, selective presynaptic dopamine autoreceptor antagonist. |
104391-26-6 |
DC21587 |
RR 601
A potent, selective protein tyrosine phosphatase DUSP5, PTP1B and SHP-2 inhibitor with IC50 of 36 uM, 2.1 and 1.1 uM respectively, 8-fold selectivity for PTP1B versus DUSP5. |
1970119-63-1 |
DC26105 |
AGN-195183
A potent, selective RARα agonist. |
367273-07-2 |
DC22996 |
LE-540
A potent, selective RARβ antagonist that inhibits RA-induced transcriptional activation of RARβ, but not RARα, RARγ or RXRα on a variety of RA response elements. |
188645-44-5 |
DC22547 |
RIPK2-IN-2
A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.. |
1581270-11-2 |
DC11942 |
VU591
A potent, selective renal outer medullary potassium channel (ROMK, Kir1.1) inhibitor with IC50 of 0.24 uM in T1+ flux assays. |
1222810-74-3 |
DC22701 |
SEW2871
A potent, selective S1P1 receptor full agonist with EC50 of 13.8 nM, with no activites at the S1P2-5 receptors. |
256414-75-2 |
DC11560 |
SPM-242
A potent, selective S1P3 antagonist with Ki of 0.25 nM. |
|
DC11561 |
SPM-242 racemate
A potent, selective S1P3 antagonist with Ki of 0.25 nM. |
749263-43-2 |
DC22702 |
PD144418
A potent, selective sigma 1 ligand with Ki of 0.08 nM, >3000-fold selectivity over sigma 2 (Ki=1377 nM). |
154130-99-1 |
DC22663 |
CB-64D
A potent, selective sigma-2 receptor agonist with Ki of 16.5 nM, 200-fold selectivity over sigma 1 (Ki=3063 nM). |
157752-20-0 |
DC22703 |
CM 764
A potent, selective sigma-2 receptor agonist with Ki of 3.5 nM, 25-fold selectivity over sigma-1 receptors (Ki=86.6 nM). |
1350296-29-5 |
DC21700 |
Stafib-1
Featured
A potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 44 nM, >50-fold selectivity over STAT5a.. |
1688703-26-5 |
DC23946 |
PAP-1
Featured
PAP-1 is a selective inhibitor of Kv1.3, voltage-gated K+ channel. PAP-1 (EC50=2 nM) potently inhibits human T effector memory cell proliferation and delayed hypersensitivity. IC50 value: 2 nM (EC50) [1]in vitro: blocks Kv1.3 in a use-dependent manner, with a Hill coefficient of 2 and an EC50 of 2 nM, by preferentially binding to the C-type inactivated state of the channel. PAP-1 is 23-fold selective over Kv1.5, 33- to 125-fold selective over other Kv1-family channels, and 500- to 7500-fold selective over Kv2.1, Kv3.1, Kv3.2, Kv4.2, HERG, calcium-activated K+ channels, Na+,Ca2+, and Cl- channels [1]. The blockade of Kv1.3 results in membrane depolarization and inhibition of TEM proliferation and function. In this study, the in vitro effects of PAP-1 on T cells and the in vivo toxicity and pharmacokinetics (PK) were examined in rhesus macaques (RM) with the ultimate aim of utilizing PAP-1 to define the role of TEMs in RM infected with simian immunodeficiency virus (SIV). Electrophysiologic studies on T cells in RM revealed a Kv1.3 expression pattern similar to that in human T cells. Thus, PAP-1 effectively suppressed TEM proliferation in RM [2].in vivo: PAP-1 does not exhibit cytotoxic or phototoxic effects, is negative in the Ames test, and affects cytochrome P450-dependent enzymes only at micromolar concentrations. PAP-1 potently inhibits the proliferation of human TEM cells and suppresses delayed type hypersensitivity, a TEM cell-mediated reaction, in rats [1]. When administered intravenously, PAP-1 showed a half-life of 6.4 hrs; the volume of distribution suggested extensive distribution into extravascular compartments. When orally administered, PAP-1 was efficiently absorbed. Plasma concentrations in RM undergoing a 30-day, chronic dosing study indicated that PAP-1 levels suppressive to TEMs in vitro can be achieved and maintained in vivo at a non-toxic dose [2]. |
870653-45-5 |
DC23927 |
MIM1
A potent, selective small molecule Mcl-1 inhibitor that selectively targets the BH3-binding groove of Mcl-1. |
509102-00-5 |
DC23623 |
PF-06761281
Featured
A potent, selective sodium-coupled citrate transporter (NaCT or SLC13A5) with IC50 of 0.51 uM, >20-fold selectivity over NaDC1 and NaDC3. |
1854061-19-0 |